Whereas membrane proteins make up ∼23% of the human proteome, it is estimated that membrane proteins constitute more than 60% of current drug targets. With membrane proteins forming such a high percentage of drug targets relative to their abundance within the proteome, it is little wonder that drug companies need to rapidly access high quality membrane proteins for their drug discovery process. Newly devised technologies, such as rapid gene synthesis, novel detergents, and protein thermostabilisation strategies allow conventionally 'undruggable' membrane proteins to be drugged. In this review, we survey the state-of-the-art gene design, expression and purification strategies, and protein thermostabilisation methods used within a modern drug discovery programme, with a focus on G protein-coupled receptors.

中文翻译：

---

工业上膜蛋白的生产：GPCR的例子。

膜蛋白约占人类蛋白质组的23％，据估计膜蛋白构成了当前药物靶标的60％以上。相对于蛋白质组中膜蛋白的丰度，膜蛋白形成了如此高比例的药物靶标，因此毫不奇怪，制药公司需要为他们的药物开发过程快速访问高质量的膜蛋白。新开发的技术，例如快速的基因合成，新型去污剂和蛋白质热稳定化策略，使传统上“难以吸收”的膜蛋白得以药物化。在这篇综述中，我们调查了现代药物发现计划中使用的最新基因设计，表达和纯化策略以及蛋白质热稳定方法，重点是G蛋白偶联受体。